← signals
2026-07-13·TSM·earnings surprise
highup

TSMC reported a 67.9% year-on-year surge in June revenue to NT$442.68 billion, with first-half revenue up 35.6% to...

TSMC reported a 67.9% year-on-year surge in June revenue to NT$442.68 billion, with first-half revenue up 35.6% to NT$2.4 trillion, exceeding high-end guidance (Source: CNBC).

window 15devidence 105confidence score 100price TSM $434.11

confidence score

Strong evidence: 52 independent source classes support this read.

100
high confidence52 independent source classesnewsothermarketpasses publish gate
priced-in check

TSM has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-07-107d n/a45d n/a90d +17%yahoo

signal brief

TSMC reported a 67.9% year-on-year surge in June revenue to NT$442.68 billion, with first-half revenue up 35.6% to NT$2.4 trillion, exceeding high-end guidance (Source: CNBC). The company also announced plans to add two advanced packaging plants in Chiayi Science Park, with all four plants expected to generate over $9.35B in annual output (Source: Reuters). SemiAnalysis analyst Sravan Kundojjala noted that TSMC's Q2 revenue exceeded its high-end guidance and that AI demand remains tight, with N3 capacity sold out (Source: CNBC). TSMC's CoWoS bottlenecks are redirecting work to other players, but TSMC maintains a dominant 73% pure-foundry market share (Source: Digitimes). These developments underscore TSMC's central role in AI infrastructure spending and strong demand momentum ahead of its July 16 earnings call.

What the sources said:

  • Reuters: "TSMC will add two advanced chip packaging plants in the Chiayi Science Park" Reuters.
  • CNBC: "TSMC reported a 67.9% year-on-year rise in its June sales" and "the demand supply situation in AI is still quite tight" (SemiAnalysis analyst) CNBC.
  • Digitimes: "TSMC's tight advanced-node and CoWoS capacity is redirecting work... but still trail TSMC in technology, yields and integrated service" Digitimes.

source data used

spillover entities

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.